BioWorld - Sunday, January 19, 2020

Deals and M&A
%{topic} RSS Feed RSS

Deal partnership chain link
Up to $1.1B in milestones

Morphosys banks $750M up front plus $150M in stock sale as Incyte swoops in on tafasitamab

January 13, 2020
By Cormac Sheridan
No Comments
Ten days after its JAK1 inhibitor, itacitinib, failed a phase III trial in acute graft-vs.-host-disease (GVHD), Incyte Corp. has finalized a deal that could provide an alternative growth path. It is paying Morphosys AG $750 million up front, investing $150 million in its stock and is on the hook for up to $1.1 billion in milestones for a 50% interest in U.S. rights to the CD19-targeting antibody tafasitamab (MOR-208) and for 100% of the rights in all other territories.
Read More
1-10-sebacia.png

Sebacia names CEO, picks up Sienna assets

January 10, 2020
By Liz Hollis
No Comments
Duluth, Ga.-based Sebacia Inc., which is focused on dermatology and aesthetics, has introduced its new CEO and reported the acquisition of all assets related to Sienna Biopharmaceuticals Inc.'s silver photoparticle technology, which is being reviewed by the FDA for light hair removal.
Read More

Amunix builds Roche ties with new $1.5B non-oncology deal

January 10, 2020
By Michael Fitzhugh
No Comments
California's Amunix Pharmaceuticals Inc. said Roche Holding AG has agreed to license its therapeutic half-life extension technology, XTEN, for an effort to discover and develop new non-oncology therapies. The deal, which includes $40 million up front, plus up to $1.5 billion in development and sales milestones, builds on a previous technology evaluation agreement the companies first inked in 2013.
Read More

Popular Stories

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe